ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
You play a critical role in the ABECMA treatment process, helping RRMM patients navigate their journey with ABECMA. Get information and tools you need to help support your patients below.
From the treatment process to adverse event monitoring and management information, it’s here—so you can continue to guide your patients throughout their treatment journey.
RRMM=relapsed/refractory multiple myeloma.
ABECMA is provided as a one-time infusion containing a suspension of CAR-positive T cells in 1 or more infusion bags. The dose range is 300 to 460 x 106 CAR-positive T cells. ABECMA is an autologous product. The treatment process includes leukapheresis, manufacturing, administration, and adverse event monitoring.
Lymphodepletion should begin 5 days before ABECMA is administered.
Administer the lymphodepleting chemotherapy regimen of cyclophosphamide 300 mg/m2 IV and fludarabine 30 mg/m2 IV daily for 3 days. ABECMA should be administered 2 days after the completion of lymphodepleting chemotherapy.
Delay the infusion of ABECMA up to 7 days if a patient has any of the following conditions:
Generally, ABECMA infusion takes 30 minutes to 1 hour. ABECMA infusion usually takes up to 30 minutes for each infusion bag. A patient’s dose of ABECMA may be given in 1 or more infusion bags.
Yes; 30 to 60 minutes before ABECMA infusion, you should administer acetaminophen (650 mg orally) and diphenhydramine (12.5 mg IV or 25 to 50 mg orally, or another H1-antihistamine).
Avoid prophylactic use of dexamethasone or other systemic corticosteroids, as they may interfere with the activity of ABECMA.
For signs and symptoms of CRS and neurologic toxicities, patients should be monitored at least daily for 7 days following ABECMA infusion at the certified healthcare facility where they received treatment. Patients should be instructed to stay within 2 hours of the certified healthcare facility for at least 4 weeks after infusion for monitoring.
ABECMA is a BCMA-directed, genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with RRMM after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
BCMA=B-cell maturation antigen; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; IV=intravenously; MOA=mechanism of action.